Company
Visen
With more humane, innovative therapies, enabling endocrine patients to live the life they aspire to
Also known as VISEN Pharmaceuticals
- Status
- IPOas of 2026-09-18Source (opens in a new tab)
- Headquarters
- Suzhou, China
- Founded
- 2018
Claim, correct or request removal
Record updated 18 September 2026
About
维昇药业 (Visen Pharmaceuticals) is an innovative biopharmaceutical company focused on endocrine-related therapeutic areas, dedicated to using more humane, innovative therapies to give endocrine patients a better treatment experience and better outcomes, so that they can live the lives they long for. Putting patients' needs first, Visen is committed to providing first-in-class or best-in-class endocrine disease products and treatment solutions.
Funding snapshot
- Total raised
- $150MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series B, $150M2021-01
Funding rounds
- Series B
- $150M2021-01, Company stated
About the company
- Status notes
- 在香港交易所主板上市，股份代码2561.HK
Products
- Other
- 帕罗培特立帕肽
- Other
- 那韦培肽
- Other
- 隆培生长激素
Loading relationship preview